The use of katadolon in patients with spondylogenic dorsalgia

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 106, Issue 11, 2006, Pages 46-48

  Kamchatnov, P R ^a   Batysheva, T T ^a   Ganzhula, P A ^a   Gaponova, O V ^a   Zhuravleva, E Yu ^a   Ismailov, A M ^a   Kostenko, E V ^a   Boiko, A N ^a  

^a NONE

Author keywords

Katadolon; Spondylogenic dorsalgia

Indexed keywords

EID: 33845942917     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Russian source
2. Russian source
3. Russian source
4. Breivik H., Collett B. Venlafridda V. et al. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 4: 287-333.
5. Engel J. Flupirtine - a new central acting analgesic with unique chemical structure. Postgrad Med 1987; 63: Suppl 3: 15-17.
6. Friedel H.A., Filton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993; 45: 4: 548-569.
7. Frymoyer J.D. Back pain and sciatica. N Engl J Med 1988; 318: 291-300.
8. Herrmann W.M., Kern U., Aigner M. On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis. Postgrad Med J 1987; 63: 87-103.
9. Herrmann W.M., Hiersemenzel R., Aigner M. et al. Long-term tolerability of Flupirtine. Fortschr Med 1993; 111: 15: 3-13.
10. Heusinger J.H. Efficacy and tolerance of flupirtine and pentazocine in two multicentre trials. Postgrad Med J 1987; 63: 71-79.
11. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
12. Kornhuber J., Bleich S. Wiltfang J. et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. J Neurol Transm 1999; 106: 9/10: 857-867.
13. Low Back pain initiavite. WHO 1999.
14. Mastronardi P., D'Onofrio M., Scanni E. et al. Analgesic activity of flupirtine maleate: a controlled double-blind study with diclofenac sodium in orthopaedics. J Int Med Res 1988; 16: 338-348.
15. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness. Results of a postmarket surveillance study. Fortschr Med Orig 2003; 121: 1: 11-18.
16. Nachemson A.L. Newest knowledge of low back pain. A critical look. Clin Orthop 1992; 279: 8-20.
17. Pengel L., Herbert R.D., Maher C.G., Refshauge K.M. Acute low back pain: systematic review of its prognosis. BMJ 2003; 327: 9-12.
18. Schuster D., Schwarz M., Block M. et al. Flupirtine: a review of its neuroprotective and behavioral proprties. CNS Drugs 1997; 12: 13-18.
19. 2 - adrenergic mechanisms are involved in the depressent action of flupirtine on spinal reflexes in rats. Eur J Pharmacol 1995; 276: 247-255.
20. Szelenyi I., Nickel B., Borbe H.O., Brune H. Mode of antinociceptive action on flupirtine in the rats. Br J Pharmacol 1989; 9: 835-842.
21. Weiser T., Szelenyi I., Nickel B., Weinrich M. In vitro and in vivo findings about the muscle relaxing properties of flupirine. Naunyn-Schmiedeberg Arch Pharmacol 1992; 246: Suppl 1: 22-27.
22. Worz R., Stroehmann I. et al. Ruckemschmerzen: Leitlinien der medikamentosen therapie. Munch Med Wschr 2000; 142: 5: 27-33.